Photoactivatable Lipid-based Nanoparticles as a Vehicle for Dual Agent Delivery

The invention relates to novel lipid-based nanoparticles (liposomes) for use in targeted, on demand and on site drug delivery. The particles include a wall surrounding a cavity, wherein the wall is comprised of:

1. A lipid bilayer comprising 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC_8,9PC), dipalmitoylphosphatidylcholine (DPPC), and 1,2-distearoyl-sn-glycero-3-

phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000), and

1. A tetrapyrollic photosensitizer, 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) within the lipid bilayer.

The photosensitive lipid nanoparticles are capable of containing water-soluble agents (e.g., topotecan) in their cavity and designed to be 80-200nm in diameter. The release of agents is triggered by the disruption of the lipid bilayer when light (near-infrared wavelength of 650-670nm) is discretely applied. The concurrent activation of the photosensitizing agent, HPPH may be advantageous in the treatment of certain cancers, especially since this agent possesses therapeutic ability. The inventors have also shown the cytotoxicity of the lipid nanoparticles in T24 bladder cancer cells in the presence and absence of light, drug, and HPPH. The lipid nanoparticles containing the water-soluble agent, topotecan, and HPPH, in the presence of light exhibit superior toxicity as compared to either lipid-nanoparticle encapsulated topotecan or HPPH alone.

                                                 

 

Potential Commercial Applications:		Competitive Advantages:
The nanoparticles can be used for targeted multiple drug delivery Cancer, cardiovascular and musculoskeletal disorders, infectious disease Cosmetic/topical products		Stable nanoparticles Platform technology applicable to several major, unmet medical needs Nanoparticles can be activated upon demand to release a therapeutic agent at a desired site The concurrent activation of the photosensitizing agent, HPPH may be advantageous in the treatment of certain types of cancer Potential for topical products having shorter time- and cost-to-market; additional licensing opportunities in the cosmetics sector Compared with standard emulsions and other types of particle-based delivery, better control of – and prolonged – delivery Faster degradation versus particles comprised made from many other polymeric formulations Potential for superior tolerability

Development Stage:
Pre-clinical (in vivo)

Inventors:

Anu Puri (NCI)  ➽ more inventions...

Robert Blumenthal (NCI)  ➽ more inventions...

Amit Joshi (NCI)  ➽ more inventions...

Darayash Tata (NCI)  ➽ more inventions...

Mathias Viard (NCI)  ➽ more inventions...


Intellectual Property:

Collaboration Opportunity:
Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-482-2013
Updated: Aug 15, 2017